The overall aim of the trial is to evaluate the efficacy of licensed targeted therapies in unlicensed indications,in rare adult,paediatric and TYA cancers with actionable genomic alterations (including common cancers with rare actionable alterations) and to identify genomic,transcriptomic and immune contextual influences on response to therapy. The ultimate aim is to transition positive findings ...

GO TO STUDY

Primary central nervous system lymphoma (PCNSL) is a rare type of brain tumour. It is an aggressive type of non-Hodgkin lymphoma that is found only in the brain or spinal cord. PCNSL is often treated with high-doses of chemotherapy. The first treatment doesn’t work for some patients (called ‘refractory’), and the lymphoma can come back (called ‘relapse’). Refractory or relapsed (RR) PCNSL is much more difficult to treat. There is currently no standard treatment for RR-PCNSL and further chemotherapy ...

GO TO STUDY

This is a pragmatic, a non-interventional, prospective observational cohort study planned to run for 6 years (Includes pregnancy and to the child’s 5th birthday). This study will build on the infrastructure formed as part of the main OPTIMISE:MS study, adding pregnancy-focused pharmacovigilance. Due to the need to contact healthcare providers for information over and above that recorded in the neurological records, this study needs additional approvals to the main study. The pregnancy study will meet the needs ...

GO TO STUDY

Head and neck cancer is a disease where tumours arise in the mouth, back of the nose, throat, or voice box. It is treated by combinations of surgery, radiotherapy and chemotherapy. Currently, people who finish treatment have a clinic review every 2-6 months for 5 years to check for the cancer coming back (recurrence). Finding recurrence early increases the chance of treating it successfully. However, many patients feel they are seen too frequently, and this can increase their worry about ...

GO TO STUDY

Treatments for breast cancer have been increasingly successful. However for patients who have recurrence of their cancer prognosis is still poor. This study will look at patients with treatable cancer that was estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-). Patients who have completed any surgery, chemotherapy and radiotherapy and are taking long-term endocrine (hormone) therapy will be approached. Participants will undergo up to 3 years of circulating tumour DNA (ctDNA) testing. It ...

GO TO STUDY

The ASCEND PLUS trial aims assess whether treatment with oral semaglutide reduces the risk of cardiovascular events,and other complications of diabetes,in individuals aged at least 55 years,with type 2 diabetes,without a history of a myocardial infarction or stroke,and without any upper or lower HbA1c threshold. The trial will use mail-based invitation to randomise approximately 20,000 people with type 2 diabetes,and no history of myocardial infarction or stroke,all recruited within the UK and follow them during a scheduled treatment period with ...

GO TO STUDY

Group B Streptococcus (GBS) is a bacterium (a bug) that causes serious infections in young infants across the world. In 2015 it was estimated that there were at least 319,000 infants under 3 months of age with GBS disease worldwide, resulting in 90,000 deaths and at least 10,000 children with long term disabilities. Around 20% of all pregnant women carry GBS in their vagina and bowel and babies are exposed to GBS bacteria around the time of birth. The options ...

GO TO STUDY

The primary aim of TARGET National is to establish a national framework to offer molecular profiling of circulating tumor DNA and/or tumour tissue (optional) to patients with advanced solid cancers referred to any of the Experimental Cancer Medicine Centres (ECMCs) across the UK, in order to help decision making for allocation to molecularly targeted experimental cancer treatments. Patients will be allocated treatment using a national Molecular Tumour Board to find the most suited therapies based on their molecular profiling results. ...

GO TO STUDY

This is a phase II,multicentre,single arm,open label pilot study to assess the safety and efficacy of acalabrutinib in combination with rituximab for previously untreated elderly frail mantle cell lymphoma patients. Patients will receive acalabrutinib and rituximab for up to six cycles. The cycle length is 28 days. Specifically,patients will receive acalabrutinib,orally,at a dose of 100 mg twice daily for 28 days and rituximab 375 mg/m2 intravenously on day 1 (+/-3) of each cycle.* Patients with any degree ...

GO TO STUDY

Cancer of the oesophagus, the stomach and the bowel are often diagnosed at advanced stage when curative treatment is no longer possible, or can only be achieved by major surgical procedures, often combined with chemo- and radiotherapy, all of which have a huge impact on the patient’s quality of life. Patients with precursor conditions of oesophageal cancer (so-called Barrett Oesophagus) have shown clear benefit from regular surveillance of the respective areas by special camera tests. Both, early detection and treatment ...

GO TO STUDY